Vor Biopharma
Yahoo Finance • 18 hours ago
Vor Biopharma registers 51M shares for resale linked to RemeGen deal and PIPE financing
* Vor Biopharma (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) has filed a prospectus to register 51M shares of common stock for potential resale by existing stockholders. * Includes: 16M shares issuable under a warrant granted to... Full story
Yahoo Finance • 23 hours ago
Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects
[Wall Street,NYC] Lisa-Blue/iStock via Getty Images Vor Biopharma (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prosp... Full story
Yahoo Finance • 6 days ago
Vor Biopharma trading halted on Thursday, news pending
[Reflective keychain with text stop lies on hundred dollar bills, business] Victoria Kotlyarchuk /iStock via Getty Images * Vor Biopharma (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) trading was halted on September 18, 2025, pendi... Full story
Yahoo Finance • 8 days ago
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusi... Full story
Yahoo Finance • 8 days ago
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in Ch... Full story
Yahoo Finance • 13 days ago
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host vi... Full story
Yahoo Finance • 29 days ago
Vor Biopharma shareholders approve equity plan changes and reverse stock split authorization
Vor Biopharma Inc. (NASDAQ:VOR), a biotechnology company currently valued at $263 million, announced Wednesday that its shareholders approved several proposals at a special meeting held Monday, according to a statement based on a recent SE... Full story
- T
Mentioned:
Yahoo Finance • last month
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and August 18, 2025, the C... Full story
Yahoo Finance • last month
Vor Bio, RemeGen succeed in trial for telitacicept in China
[Hand inserts a molecule into DNA.] Natali_Mis/iStock via Getty Images Shares of Vor Bio (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a late stage... Full story
Yahoo Finance • last month
Telitacicept meets primary endpoint in China's phase 3 Sjögren's trial
CAMBRIDGE, Mass. - Vor Bio (NASDAQ:VOR) announced Wednesday that its collaborator RemeGen Co., Ltd (HKEX:9995, SHA:688331) achieved the primary endpoint in a Phase 3 clinical study of telitacicept for primary Sjögren’s disease in China. Re... Full story
Yahoo Finance • last month
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's dise... Full story
Yahoo Finance • 2 months ago
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Off... Full story
Yahoo Finance • 2 months ago
Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board
We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to... Full story
Yahoo Finance • 2 months ago
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target
Vor Biopharma Inc. (NASDAQ:VOR) is one of the hot penny stocks to invest in now. In a report released on June 30, Swayampakula Ramakanth from H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR) to a Buy with a price target of $3.00. T... Full story
Yahoo Finance • 2 months ago
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Co... Full story
Yahoo Finance • 2 months ago
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development f... Full story
Yahoo Finance • 3 months ago
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company’s transformation and growth in autoimmune disease CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bi... Full story
Yahoo Finance • 3 months ago
Wednesday Sector Leaders: Biotechnology, Railroads
In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 3.5%. Leading the group were shares of Vor Biopharma, up about 22.7% and shares of Prime Medicine up about 19.6% on the day. Also showing relativ... Full story
Yahoo Finance • 3 months ago
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Direct... Full story
